<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151254</url>
  </required_header>
  <id_info>
    <org_study_id>UHN REB 06-0159 B</org_study_id>
    <nct_id>NCT01151254</nct_id>
  </id_info>
  <brief_title>Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation</brief_title>
  <official_title>Comparison of Propofol Based Anesthesia and Postoperative Sedation (PA) Versus Volatile Anesthetics Based Anesthesia and Postoperative Sedation (VA) in Cardiac Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients undergoing cardiac surgery require intraoperative anesthesia and short-term
      postoperative sedation with anesthetic agents after the procedure when patient is in the
      intensive care unit (ICU). The clinical data obtained so far are concentrating on
      intraoperative use volatile agents (preconditioning) resulting in better postoperative
      cardiac function and less release of biochemical markers of myocardial damage. There are no
      studies investigating whether postoperative use of volatile agents (post conditioning) in
      cardiac surgical population is improving outcomes. The aim of the present study is to compare
      total intravenous anesthesia and postoperative sedation versus total volatile anesthesia and
      postoperative sedation in cardiac surgical population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite primary end point of the trial will be the development of enzymatic signs of myocardial injury or MI, postoperative low output syndrome, or both. Enzymatic MI will be determined after obtaining serial measurements of troponin.</measure>
    <time_frame>Measurements of troponin levels will be after induction of anesthesia (baseline) and at 0, 2, 4, 8, and 24 h after arrival into the ICU.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of sedation</measure>
    <time_frame>Post ICU arrival POD 0 to discharge (2hours to on average 5-7 days until discharge)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delirium</measure>
    <time_frame>Post ICU arrival POD 0 to discharge (2hours to on average 5-7 days until discharge)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to readiness for extubation, time to extubation</measure>
    <time_frame>Post ICU arrival POD 0 to discharge (2hours to on average 5-7 days until discharge)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay within ICU, readiness for discharge from the unit</measure>
    <time_frame>Post ICU arrival POD 0 to discharge (2hours to on average 5-7 days until discharge)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>PA-Intravenous Sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol based total intravenous anesthesia and postoperative sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volatile sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total inhalational anesthesia and postoperative sedation with the AnaConda device</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoflurane/sevoflurane</intervention_name>
    <description>Volatile for sedation in the CVICU while intubated</description>
    <arm_group_label>Volatile sedation</arm_group_label>
    <other_name>2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane</other_name>
    <other_name>2,2,2-trifluoro-1-[trifluoromethyl]ethyl fluoromethyl ether</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol for sedation in the CVICU</description>
    <arm_group_label>PA-Intravenous Sedation</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients scheduled for coronary artery bypass graft surgery with good ventricular
             function (grade 1-2 ventricle)

          -  Signed informed consent

        Exclusion criteria:

          -  Patients undergoing valvular surgery

          -  Severe kidney or liver disease (creatinine &gt; 2.5mg.dL-1 and bilirubin &gt; 2 mg.dL-1)

          -  Patients with known hypersensitivity to any of the trial drugs (propofol, volatile
             anesthetics), e.g. propofol allergy or malignant hyperthermia (induced by volatile
             anesthetics)

          -  Patient with poorly controlled diabetes or on oral anti-diabetic medication (inhibit
             preconditioning caused by volatile anesthetics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcin Wasowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital, University Health Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hopsital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>February 11, 2014</last_update_submitted>
  <last_update_submitted_qc>February 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Sedation</keyword>
  <keyword>Intensive care</keyword>
  <keyword>Volatile anesthesia</keyword>
  <keyword>Intravenous anesthesia</keyword>
  <keyword>Pre and post conditioning after cardiac surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

